Search

To the Editor: In September 1993 we reported on the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial, which involved 41,021 patients with acute myocardial infarction (Sept. 2 issue).1 In that report, we erred in stating that there was a 99.9 percent level of completeness of “30-day mortality outcomes”; this should have read “in-hospital outcomes.” Since our initial report, we have received complete data on outcomes at 30 days in all but 98 patients (0.2 percent) and there has been refinement in the data base for variables for which either data were missing or . . .

Excerpt To the Editor:Kase and colleagues (Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.Ann Intern Med. 1990;112:17-21) recently presented six cases o...